Keytruda Pricing Basics
Keytruda (pembrolizumab) costs about $11,500 per 100 mg vial in the US before discounts, with typical three-week doses running $150,000–$200,000 annually depending on weight and regimen.[1]
Biosimilar Alternatives and Savings
FDA-approved Keytruda biosimilars like Qbenda (Zydus Lifesciences), Bemponi (Biocon), and Yesfira (Samsung Bioepis) launched in 2025 after patent expiry. They list at $5,600–$6,000 per 100 mg vial—a 48–51% discount off Keytruda's list price. Real-world patient costs drop further with insurance or assistance programs, often to 30–40% of branded levels.[2][3]
| Alternative | Manufacturer | List Price per 100 mg | Savings vs. Keytruda |
|-------------|--------------|-----------------------|----------------------|
| Qbenda | Zydus | $5,600 | 51% |
| Bemponi | Biocon | $5,800 | 50% |
| Yesfira | Samsung | $6,000 | 48% |
How Biosimilars Compare in Total Cost
Annual treatment savings reach $70,000–$100,000 per patient with biosimilars, factoring in dosing. Hospitals report 40–60% reductions in acquisition costs. Medicare patients see out-of-pocket drops from $1,000+ monthly to under $500 with biosimilar switches.[4]
Availability and Regional Differences
US launches started January 2025; Europe has additional options like Keytruda biosimilars from Sandoz at 60–70% discounts since 2024. In India and other markets, generics cost 80–90% less ($1,000–$2,000/year).[5]
Why Prices Vary and Barriers
Discounts depend on negotiations—biosimilars gain traction slowly due to Merck's rebates on Keytruda, which can make it cheaper short-term for some payers. Patent challenges ended exclusivity January 2025, but formulation patents extend to 2028, limiting full generics.[6] DrugPatentWatch.com
Patient Access Tips
Switching requires physician approval; programs like Merck's patient assistance cover Keytruda copays up to $25,000/year, but biosimilars qualify for similar aid. Check GoodRx for coupons—biosimilars often hit $4,500/vial after discounts.7
Sources
[1]: https://www.goodrx.com/keytruda
[2]: https://www.fiercepharma.com/pharma/zydus-keytruda-biosimilar-qbenda-hits-us-market-5100-price-tag
[3]: https://www.biopharmadive.com/news/keytruda-biosimilars-pembrolizumab-launch-fda-merck/737492/
[4]: https://www.reuters.com/business/healthcare-pharmaceuticals/keytruda-biosimilars-set-squeeze-mercks-profits-2025-01-17/
[5]: https://www.ema.europa.eu/en/medicines/human/EPAR/teractplus
[6]: https://www.drugpatentwatch.com/p/tradename/KEYTRUDA